Prostate cancer Posts - Page 11 of 80 on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Evaluating the impact on quality of life of giving enzulatumide in combination with hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

Evaluating the impact on quality of life of giving enzulatumide in combination with hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

Posted by on Dec 6, 2020 in Prostate cancer | 0 comments

In a nutshell This study investigated the quality of life after treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) with enzalutamide (Xtandi) in combination with hormone therapy. The study found that enzalutamide + hormone therapy improved the quality of life of patients, compared to hormone therapy...

Read More

Does giving radiotherapy to metastatic sites and the prostate tumor improve the outcomes of patients with prostate cancer and few metastases?

Does giving radiotherapy to metastatic sites and the prostate tumor improve the outcomes of patients with prostate cancer and few metastases?

Posted by on Nov 25, 2020 in Prostate cancer | 0 comments

In a nutshell This study aims to evaluate if giving radiotherapy to both the areas the tumor has spread (metastases), along with the prostate tumor, will improve the survival of patients with prostate cancer (PC) and few metastases (oligometastatic disease). This study suggested that this treatment could benefit patients with PC and few...

Read More

Evaluating cabozantinib plus docetaxel and prednisone in patients with metastatic castration resistant prostate cancer

Evaluating cabozantinib plus docetaxel and prednisone in patients with metastatic castration resistant prostate cancer

Posted by on Nov 15, 2020 in Prostate cancer | 0 comments

In a nutshell The study evaluated outcomes of combining cabozantinib (Cabometyx) with docetaxel (Taxotere) and prednisone (Deltasone) in treating patients with metastatic castration-resistant prostate cancer (mCRPC). The main finding was that the combination was safe and could possibly be effective in such patients. Some background Docetaxel was the...

Read More

Searching for patients with advanced prostate cancer to trial a new immune treatment.

Searching for patients with advanced prostate cancer to trial a new immune treatment.

Posted by on Nov 8, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including prostate cancer. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated. These...

Read More

The importance of timing of radiotherapy after radical prostatectomy in patients with prostate cancer

The importance of timing of radiotherapy after radical prostatectomy in patients with prostate cancer

Posted by on Oct 29, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared outcomes of adjuvant radiotherapy (AR) versus observation with salvage radiotherapy (SR) in patients with prostate cancer (PCa) after radical prostatectomy (RP). The authors found that careful observation with SR is a safer treatment after RP for preventing cancer progression. Some background RP surgically removes the...

Read More

Longer-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer

Longer-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer

Posted by on Oct 24, 2020 in Prostate cancer | 0 comments

In a nutshell This study evaluated longer-term survival rates and the safety of olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC). It found that treatment with olaparib led to significantly longer survival, especially in men with gene alterations. Some background CRPC is an especially aggressive...

Read More

Looking to recruit patients with prostate cancer that has spread to the bone to trial a radiation treatment.

Looking to recruit patients with prostate cancer that has spread to the bone to trial a radiation treatment.

Posted by on Oct 11, 2020 in Prostate cancer | 0 comments

In a nutshell This study is looking to recruit patients with prostate cancer (PC) spread to the bone to trial internal and external radiotherapy. The main outcome that will be measured is the length of time until patients need androgen deprivation therapy (ADT). This trial will be carried out in Utah, the United States.  The details PC...

Read More

Quality of life in patients with metastatic prostate cancer under cabazitaxel treatment

Quality of life in patients with metastatic prostate cancer under cabazitaxel treatment

Posted by on Oct 10, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared the quality of life (QoL) of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (Jevtana) compared to abiraterone (Zytiga) or enzalutamide (Xtandi). The authors found that cabazitaxel did not reduce QoL in such patients. Some background Patients with mCRPC...

Read More

A look at high intensity focused ultrasound removal of prostate gland: effects and complications

A look at high intensity focused ultrasound removal of prostate gland: effects and complications

Posted by on Oct 4, 2020 in Prostate cancer | 0 comments

In a nutshell This study investigated the short-term functional measures and complications for high-intensity focused ultrasound (HIFU) treatment in half of the prostate gland (hemi-gland) for patients with prostate cancer (PCa). The study showed that hemi-gland HIFU is a low-risk surgery and provides maintenance of sexual and urinary...

Read More

Ipilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer

Ipilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer

Posted by on Sep 30, 2020 in Prostate cancer | 0 comments

In a nutshell This trial was carried out to examine the effectiveness of radiotherapy followed by treatment with ipilimumab (Yervoy) in men with metastatic castrate-resistant prostate cancer  (mCRPC). The trial found that this treatment led to higher survival in these patients compared to radiotherapy followed by placebo. Some...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor